Rama Harouni
Internal Medicine · Las Vegas, NVNPI 1093793697
Payments from drug & device makers
Across 96 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$533
- AstraZeneca$391
- Lilly USA, LLC$372
- Novartis$331
- E.r. Squibb & Sons, L.L.C.$290
- Amgen$279
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,360100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $533 |
| AstraZeneca | 11 | $391 |
| Lilly USA, LLC | 11 | $372 |
| Novartis | 14 | $331 |
| E.r. Squibb & Sons, L.L.C. | 3 | $290 |
| Amgen | 8 | $279 |
| Incyte Corporation | 2 | $248 |
| GSK | 3 | $156 |
| Sanofi | 1 | $121 |
| Biogen | 1 | $96 |
| Boehringer Ingelheim | 1 | $83 |
| Abbott | 4 | $70 |
| Exact Sciences | 4 | $69 |
| Pfizer | 3 | $67 |
| Boston Scientific | 1 | $58 |
| AbbVie | 3 | $54 |
| Cleerly, Inc. | 1 | $30 |
| Biowound Solutions, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,371 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 54 | $60,299 |
| EliquisApixaban | 46 | $51,928 |
| XareltoRivaroxaban | 11 | $15,404 |
| RybelsusSemaglutide | 12 | $11,432 |
| SynthroidLevothyroxine Sodium | 21 | $2,438 |
| Rosuvastatin Calcium | 126 | $1,738 |
| Eszopiclone | 33 | $1,458 |
| Atorvastatin Calcium | 101 | $924 |
| Tamsulosin Hcl | 35 | $845 |
| Levothyroxine Sodium | 88 | $844 |
| Losartan Potassium | 83 | $815 |
| Clonazepam | 41 | $734 |
| Metoprolol Succinate | 40 | $731 |
| Gabapentin | 47 | $679 |
| Ipratropium Bromide | 17 | $644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $372 | $60,29954 claims |
| PfizerEliquis | $67 | $51,92846 claims |
| Novo NordiskRybelsus | $533 | $11,43212 claims |
| AbbVieSynthroid | $54 | $2,43821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Vrijendra HoonLas Vegas$1.8M
- Robby Ann QuintosLas Vegas$1.4M
- Kent SwaineLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.